The antigen raw material specification for Lyme disease Western blot strips centers on delivering ten defined, electrophoretically resolved Borrelia proteins at exact molecular weights. These must be consistently purified and standardized to allow clinical labs to apply the CDC-recommended interpretation criteria: for IgM, at least 2 of the 3 bands at 23, 39, or 41 kDa; for IgG, any 5 of the 10 bands at 18, 23, 28, 30, 39, 41, 45, 58, 66, and 93 kDa.
A confirmatory Lyme Western blot strip is only as reliable as its antigen composition. The non‑negotiable requirement is a precisely controlled panel of ten Borrelia burgdorferi proteins that migrate to their canonical molecular weights and deliver reproducible immunoreactivity from lot to lot. Without this standardization, interpretive criteria break down and patient results become unreliable.
The Antigen Blueprint for Lyme Confirmatory Testing
Before sourcing any material, the developer must lock in the exact protein identities and performance criteria. The ten-antigen panel is the core of the CDC two‑tiered algorithm and must be present in every run of strips.
The Ten Required Antigen Bands and Their Identities
The specification requires clear, well‑separated bands corresponding to the following molecular weights:
- 18 kDa
- 23 kDa (OspC) – the outer surface protein C, a critical immunodominant antigen for early IgM response
- 28 kDa
- 30 kDa
- 39 kDa – another major immunodominant antigen used in both IgM and IgG scoring
- 41 kDa (flagellin) – the flagellar protein, universally recognized and essential for IgM criteria
- 45 kDa
- 58 kDa
- 66 kDa
- 93 kDa
Each band must be identifiable by its calibrated molecular weight, and its identity must be verifiable with monospecific antibodies or mass spectrometry during quality control.
IgM vs. IgG Interpretation Criteria Drive Specification Tolerances
The IgM requirement—at least 2 of the 3 bands at 23 (OspC), 39, or 41 kDa—places extreme stringency on those three antigens. If any of them is under‑represented, weakly reactive, or migrates incorrectly, the kit will generate false‑negative IgM results. The IgG requirement—any 5 of all 10 bands—demands balanced representation across the entire panel so that no single antigen dominates and all contribute equally to the scoring.
Critical Raw Material Specifications
Developing a reproducible test strip means going far beyond just listing molecular weights. The raw antigen preparation must meet rigorous physical, chemical, and immunological specifications.
Purity and Homogeneity
Each protein band must originate from a single, highly purified antigen to avoid cross‑reactivity. Contaminating E. coli proteins, media components, or degraded fragments can create extra bands or smearing that interfere with interpretation. The specification must state a minimum purity (typically >95% by SDS‑PAGE/Coomassie) and require documentation that no other Borrelia proteins co‑migrate at the specified molecular weights.
Standardization of Antigen Quantity and Immunoreactivity
Every manufactured strip must display identical band intensity when probed with a standardized positive control serum. The raw material specification therefore must define:
- Total protein load per strip (the exact amount of each resolved antigen, often in nanograms).
- Immunoreactivity titers for key antigens (OspC, flagellin, 39 kDa) against a reference human serum panel, with acceptance limits.
- Quantitative densitometry targets so that automated readers can assign consistent band scores.
Strain Selection and Expression Consistency
The native lysate or recombinant source must reliably express all ten antigens in the correct proportions. If a production strain loses a plasmid encoding OspC, for example, the IgM criteria become impossible to meet. The raw material specification should mandate:
- Defined B. burgdorferi strain(s) with documented stable expression of all required proteins.
- Culture conditions controlled to avoid antigenic phase variation.
- Lot‑to‑lot consistency testing using SDS‑PAGE and immunoblotting against a panel of well‑characterized patient sera before releasing the antigen preparation.
Understanding the Trade‑offs in Antigen Sourcing
No single sourcing strategy is perfect. Developers must weigh biological authenticity against manufacturing control, and every decision impacts final strip performance.
Whole‑Cell Lysate vs. Purified Recombinant Antigens
Native lysates preserve natural post‑translational modifications and antigenic conformation, closely mirroring the patient’s actual immune response. However, they inherently suffer from batch variability and the risk of under‑representing some antigens. Recombinant proteins offer unmatched purity and lot consistency, and allow individual antigen loading to be precisely adjusted. The trade‑off is that epitope conformation may differ from the native form, potentially missing conformational antibodies. Many high‑performing kits today blend the two approaches—using recombinant proteins for the key immunodominant bands and supplementing with a controlled native fraction to cover the remaining molecular weights.
Impact on Lot‑to‑Lot Reproducibility
Even subtle changes in antigen preparation can shift band migration by a fraction of a millimeter or alter the intensity of a weakly reactive band. That can push a borderline sample from “negative” to “positive” purely because of manufacturing drift. A robust specification therefore requires real‑time stability studies, forced‑degradation samples to identify vulnerable antigens, and a reference standard strip against which every production lot is compared.
Making the Right Choice for Your Kit Development
Your antigen specification should directly reflect the clinical use case and regulatory pathway of your kit.
- If your primary focus is a standalone IgM confirmatory test: Prioritize lot‑to‑lot consistency of OspC (23 kDa), flagellin (41 kDa), and the 39 kDa antigen above all else. Over‑engineer the quality controls for these three bands, and set the tightest acceptance criteria here.
- If your primary focus is an IgG confirmatory test for late‑stage disease: Ensure balanced representation of all ten bands, because positive confirmation requires any five. A weak or missing high‑molecular‑weight antigen (e.g., 93 kDa) will directly reduce sensitivity.
- If your primary focus is a combined IgM/IgG kit for a high‑volume reference lab: Standardize the total protein profile on a single strip using a master antigen mix that satisfies both criteria simultaneously. This demands extensive bridging studies between native and recombinant sources to prove equivalency for both antibody classes.
The reliability of Lyme disease diagnosis ultimately begins with the exacting specifications you set for your antigen raw materials. A strip that faithfully reproduces the ten critical bands today, tomorrow, and five years from now is the only foundation for trust in a confirmatory result.
Summary Table:
| Specification Category | Key Requirements & Acceptance Criteria | Clinical Relevance / CDC Criteria |
|---|---|---|
| 10-Antigen Panel | 18, 23 (OspC), 28, 30, 39, 41 (Flagellin), 45, 58, 66, 93 kDa | Required for full 2-tiered confirmatory testing |
| Purity & Homogeneity | >95% purity by SDS-PAGE; no interfering bands | Prevents cross-reactivity and false positives |
| IgM Stringency | Strict control of 23 (OspC), 39, and 41 kDa bands | CDC IgM criteria requires ≥2 of these 3 bands |
| IgG Balance | Equal representation across all 10 resolved bands | CDC IgG criteria requires any 5 of the 10 bands |
| Antigen Sourcing | Recombinant, native lysate, or hybrid formulations | Controls batch reproducibility and epitope fidelity |
Accelerate Your Lyme Diagnostic Kit Development with CamelBio
Developing reliable confirmatory Western blot test strips requires standardized, high-purity antigen raw materials. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic.
Whether you need top-tier recombinant antigens, native lysates, or technical guidance to ensure lot-to-lot reproducibility for your Lyme disease assays, our team of experts is ready to assist.
Contact us today to discover how CamelBio can optimize your IVD assay performance and streamline your path to market!